1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hyperglycemia - Pipeline Review, H2 2014

Hyperglycemia - Pipeline Review, H2 2014

  • September 2014
  • -
  • Global Markets Direct
  • -
  • 47 pages

Hyperglycemia - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hyperglycemia - Pipeline Review, H2 2014’, provides an overview of the Hyperglycemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperglycemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperglycemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hyperglycemia - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperglycemia Overview 6
Therapeutics Development 7
Pipeline Products for Hyperglycemia - Overview 7
Pipeline Products for Hyperglycemia - Comparative Analysis 8
Hyperglycemia - Therapeutics under Development by Companies 9
Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10
Hyperglycemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hyperglycemia - Products under Development by Companies 14
Hyperglycemia - Products under Investigation by Universities/Institutes 15
Hyperglycemia - Companies Involved in Therapeutics Development 16
Kissei Pharmaceutical Co., Ltd. 16
Mitsubishi Tanabe Pharma Corporation 17
PhaseBio Pharmaceuticals, Inc. 18
Hyperglycemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
PE-0139 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
KR-62980 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ZLN-005 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
55-P-0251 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
FGH-10019 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Hyperglycemia - Recent Pipeline Updates 42
Hyperglycemia - Dormant Projects 43
Hyperglycemia - Product Development Milestones 44
Featured News and Press Releases 44
Dec 06, 2011: Study Shows Combination Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia In Type 1 And Type 2 Diabetes Patients 44
Nov 15, 2011: PhaseBio Announces Positive Results From Phase I/IIa Trial Of Glymera For Treatment Of Hyperglycemia In Patients With Type 2 Diabetes 44
Jul 21, 2011: Kissei Pharma Launches Glubes In Japan For Treatment Of Type 2 Diabetes 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables

Number of Products under Development for Hyperglycemia, H2 2014 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Hyperglycemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 16
Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 17
Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Hyperglycemia Therapeutics - Recent Pipeline Updates, H2 2014 42
Hyperglycemia - Dormant Projects, H2 2014 43

List of Figures

Number of Products under Development for Hyperglycemia, H2 2014 7
Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Target, H2 2014 20
Number of Products by Stage and Top 10 Target, H2 2014 21
Number of Products by Top 10 Mechanism of Action, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 23
Number of Products by Top 10 Route of Administration, H2 2014 24
Number of Products by Stage and Top 10 Route of Administration, H2 2014 25
Number of Products by Top 10 Molecule Type, H2 2014 26
Number of Products by Stage and Top 10 Molecule Type, H2 2014 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Type 2 Diabetes Mellitus: KOL Insight 2016

Type 2 Diabetes Mellitus: KOL Insight 2016

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ...

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

  • $ 5995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.